# US 2023/0055210 A1 · Formulations of creatine and cyclodextrin exhibiting improved bioavailability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055210 A1
- Document ID: US20230055210A1
- Status: Published application
- Kind: A1
- Application number: 17/970,819
- Filed: 2022-10-21
- Published: 2023-02-23
- Earliest claimed: 2018-05-21
- Assignees: Phenolics, LLC
- Applicants: Phenolics, LLC
- Inventors: Michael S. Tempesta; F. Joseph Daugherty
- Web page: https://patentgrep.com/patent/US20230055210A1

## CPC

- A61K 31/664: Amides of phosphorus acids
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Formulations of creatine, preferably phosphocreatine and most preferably disodium phosphocreatine, combined with cyclodextrin exhibit improved uptake across digestive mucosa, including intestinal, esophageal, and stomach mucosa. In particular, the formulations of the present invention are designed for protection of the creatine as they come in contact with gastric juices so as to allow thereafter for unexpectedly improved site-specific intestinal release.

## Claims

### Claim 1

A method of manufacturing a creatine supplement comprising:
co-granulating one or more creatine compounds, cyclodextrin, and a sodium source to form a granular composition having an average particle size of from 150 to 850 microns; and
coating the granular composition with methacrylate copolymers to produce a coated creatine supplement.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more creatine compounds comprises phosphocreatine and the sodium source comprises trisodium citrate.

### Claim 3 (depends on 1)

The method of claim 1, wherein the one or more creatine compounds comprises disodium phosphocreatine and the disodium moiety of the phosphocreatine constitutes all or part of the sodium source.

### Claim 4 (depends on 1)

The method of claim 1, wherein the creatine compound is selected from the group consisting of creatine monohydrate, creatine HCl and phosphocreatine, and sodium of the sodium source is present in a molar ratio of sodium to creatine of from 1:1 to 3:1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the creatine supplement comprises disodium phosphocreatine and cyclodextrin selected from the group consisting of alpha, beta and gamma cyclodextrins.

### Claim 6 (depends on 1)

The method of claim 1, wherein the creatine supplement comprises:
(i) at least one of disodium phosphocreatine or phosphocreatine;
(ii) polyethylene glycol; and
(iii) cyclodextrin selected from the group consisting of alpha, beta and gamma cyclodextrins.

### Claim 7 (depends on 1)

The method of claim 1, wherein the creatine supplement is coated with Eudraguard® as the methacrylate copolymer coating.

### Claim 8 (depends on 1)

The method of claim 1, wherein the creatine supplement comprises 85% disodium phosphocreatine, 5% polyethylene glycol, 5% cyclodextrins and is coated with a 5% by weight of the formulation coating comprising methacrylate copolymer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the coating step comprises spray drying the granular compound utilizing a fluidized bed technique.

### Claim 10 (depends on 1)

The method of claim 1, wherein the creatine supplement is used for treating a muscle wasting disorder.

### Claim 11 (depends on 1)

The method of claim 1, wherein the creatine supplement is used to enhance body muscle mass for sports performance applications, sports injury recovery or for maintenance of normal muscle tone during the aging process of a mammal.

### Claim 12

A method of manufacturing a creatine supplement comprising:
co-granulating a plurality of the following:
(i) one or more creatine compounds;
(ii) cyclodextrin; or
(iii) a sodium source;
forming a granular composition having an average particle size of from 150 to 850 microns; and
coating the granular composition with methacrylate copolymers to produce a coated creatine supplement.

### Claim 13 (depends on 12)

The method of claim 12, further comprising:
the one or more creatine compounds comprises disodium phosphocreatine;
the cyclodextrin is selected from the group consisting of alpha, beta and gamma cyclodextrins; and
the sodium source comprises trisodium citrate.

### Claim 14 (depends on 12)

The method of claim 12, wherein the sodium source comprises trisodium citrate present in a molar ratio of sodium to creatine from the creatine compound of from 1:1 to 3:1.

### Claim 15 (depends on 12)

The method of claim 12, wherein the cyclodextrin is present in a range of from 1% to 10% (w/w).

### Claim 16 (depends on 12)

The method of claim 12, wherein the creatine supplement is coated with Eudraguard® as the methacrylate copolymer coating.

### Claim 17

A method of manufacturing a creatine supplement comprising:
co-granulating a plurality of the following:
(i) creatine monohydrate, creatine HCL and/or phosphocreatine;
(ii) cyclodextrins selected from the group consisting of alpha, beta and gamma cyclodextrins; or
(iii) a sodium source;
forming a granular composition having an average particle size of from 150 to 850 microns; and
coating the granular composition with methacrylate copolymers to produce a coated creatine supplement.

### Claim 18 (depends on 17)

The method of claim 17, further comprising:
the phosphocreatine being disodium phosphocreatine;
the cyclodextrins being a mixture selected from the group consisting of alpha, beta and gamma cyclodextrins;
the sodium source comprising trisodium citrate;
the methacrylate copolymers being Eudraguard®; and
the addition of at least one of starch, maltodextrin, and polyethylene glycol to the co-granulation prior to coating.

### Claim 19 (depends on 18)

The method of claim 18, further comprising:
the disodium phosphocreatine present from 75% to 95% (w/w);
the mixture of cyclodextrins present from 1% to 10% (w/w);
the trisodium citrate present in a molar ratio of sodium to creatine from the creatine compound of from 1:1 to 3:1;
the Eudraguard® present from 1% to 10% (w/w/); and
the polyethylene glycol being PEG 3350 present from 1% to 10% (w/w).

### Claim 20 (depends on 18)

The method of claim 18, further comprising:
the disodium phosphocreatine present from 75% to 95% (w/w);
the mixture of cyclodextrins present from 0.1% to 10% (w/w);
the trisodium citrate present in a molar ratio of sodium to creatine from the creatine compound of from 1:20 to 20:1;
the Eudraguard® present from 1% to 10% (w/w); and
the polyethylene glycol being PEG 3350 present from 0.1% to 10% (w/w).
